

# Designing for Change



Institute for Healthcare Quality,  
Safety and Efficiency

SCHOOL OF MEDICINE

UNIVERSITY OF COLORADO **ANSCHUTZ MEDICAL CAMPUS**

# Financial Disclosures: NONE



*Submitted for Publication* (or will be very soon)



*Reproduced with permission* (AND terminology)



# Agenda

- 1 Choice Architecture + Nudge
- 2 Design Thinking
- 3 User-Centered Design
- 4 Pre-Mortem Analysis



# Learning Objectives

- 1 Describe different approaches for influencing behavior
- 2 Explain Design Thinking.
- 3 Recognize the importance of user-empathy in good design.
- 4 List the steps of a user-centered design process.
- 5 Explain the purpose and process of a pre-mortem analysis.
- 6 Recognize the importance of ensuring healthcare interventions are safe.





Session	Session Overview
<b>Quality Improvement &amp; Change Management</b>	<ul style="list-style-type: none"><li>• Basics of Quality Improvement</li><li>• Step-wise, practical implementation guide</li><li>• Change Management framework overview for driving change</li></ul>
<b>Applied Patient Safety</b>	<ul style="list-style-type: none"><li>• Guide the development and participation in a systems-based case review conference.</li></ul>
<b>Designing for Change</b>	<ul style="list-style-type: none"><li>• Understanding the problem and the people involved</li><li>• Design thinking and choice architecture</li><li>• User-centered design methodology</li><li>• Pre-mortem analysis to identify the right solutions for the right problem</li></ul>
<b>Acquiring Data to Drive Change</b>	<ul style="list-style-type: none"><li>• Data sources to track improvement</li><li>• Data analysis and organization</li><li>• Data visualization</li></ul>
<b>Spreading Change Locally and Nationally</b>	<ul style="list-style-type: none"><li>• Diffusion of innovation framework</li><li>• QI vs. research</li><li>• Strategies for dissemination and publication</li><li>• Grant opportunities</li></ul>
<b>Coaching and Teaching Quality Improvement</b>	<ul style="list-style-type: none"><li>• How to coach QI teams</li><li>• Identifying and troubleshooting common QI missteps</li></ul>









**You don't know the  
best solutions...but  
your users do!**



**You must talk to  
them to find out.**



**There are methods  
for how to get the  
best out of your  
users.**



**It is critical to  
ensure your  
interventions are  
*safe before*  
implemented.**



# user noun

us·er ('yü-zər 🗣️)

a person who uses a product or service



<https://www.merriam-webster.com/dictionary/user>

Photo Credit: <https://twitter.com/mkheck/status/1020149647665491970>





# YOU $\neq$ USER

*False-consensus effect:* people's tendency to assume that others share their beliefs and will behave similarly in a given context.

<https://www.nngroup.com/articles/false-consensus/>



## Attention (1)



### ! Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

**RECOMMENDATION:** Consider starting a statin medication.

This is a best practice at our institution.

 [Open hyperlipidemia treatment pathway](#)



Dismiss



# Basic Principles for Effective\* Design

\*Effective = changes usual behavior







## (Humans are) Lazy, Forgetful Creatures of Habit

Being a lazy, forgetful creature of habit is completely rational. We only have so much energy and attention, and we have ever increasing demands on it. Why should you do anything that requires more work? Why should you go out of your way? Or commit something to memory, when Google will remember it for you?

Erika Hall

Author of Conversational Design and Just Enough Research


<https://medium.com/research-things/lazy-forgetful-creatures-of-habit-2758e6976d4>

<https://unsplash.com/photos/GTXvpZ2eTdA>





# THE FORGETTING CURVE




Ebbinghaus, Hermann (1913). *Memory: A Contribution to Experimental Psychology*.  
Translated by Ruger, Henry; Bussenius, Clara. New York city, Teachers college,  
Columbia university.

<https://elearningindustry.com/forgetting-curve-combat>



# The Hierarchy of Intervention Effectiveness



**WHO Surgical Safety Checklist**  
(adapted for England and Wales)


National Patient Safety Agency  
National Reporting and Learning Service

SIGN IN (to be read out loud)	TIME OUT (to be read out loud)	SIGN OUT (to be read out loud)
<b>Antiseptic technique of practitioners</b> <input type="checkbox"/> Has the antiseptic confirmed to the identity, site, procedure and consent? <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Correct type of surgical intervention</b> <input type="checkbox"/> Correct type of surgical intervention <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Patients and Relatives of Risk</b> <input type="checkbox"/> Patients and Relatives of Risk have been informed of the operating state <input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Is the surgical site marked?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Surgeon, Anaesthetist and Registered Practitioner</b> <input type="checkbox"/> Are the names of the surgeon, anaesthetist and registered practitioner verbally confirmed? <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Support, Anaesthetist and Registered Practitioner</b> <input type="checkbox"/> Support, Anaesthetist and Registered Practitioner verbally confirmed with the team <input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Are the equipment and medication checked complete?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Are there any critical or unexpected steps planned?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	<b>What are the recovery and management of this patient?</b> <input type="checkbox"/> What are the recovery and management of this patient? <input type="checkbox"/> Yes <input type="checkbox"/> No

This checklist contains the core content for England and Wales



# The Hierarchy of Intervention Effectiveness




## What about electronic alerts?





# The Hierarchy of Intervention Effectiveness



BestPractice Advisory - Roo, Koda

**Attention (1)**

Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

**RECOMMENDATION:** Consider starting a statin medication.


This is a best practice at our institution.

[Open hyperlipidemia treatment pathway](#)

Dismiss



# The Hierarchy of Intervention Effectiveness



### CT Low Dose Chest CT For Annual Lung Cancer Screening

Accept Cancel

Status: Normal Standing **Future**

Expected Date:  Today Tomorrow 1 Week 2 Weeks 1 Month 3 Months 6 Months ☐ Approx.

Expires: 9/13/2023 1 Month 2 Months 3 Months 4 Months 6 Months **1 Year** 18 Months

Priority: Routine **Routine** STAT

Class: Ancillary Performed **Ancillary Performed** Hospital Performed External

Reason for Exam:

- ☐ Lung cancer screening, < 20 pk-yr smoking history (Age >= 50y)
- ☐ Lung cancer screening, >= 20 pk-yr smoking history (Age >= 50y)
- ☐ Lung nodule, < 6mm, high cancer risk
- ☐ Lung nodule, < 6mm, high cancer risk, stable on prior exam
- ☐ Lung nodule, < 6mm, low cancer risk
- ☐ Lung nodule, > 8mm
- ☐ Lung nodule, 6-8mm
- ☐ Lung nodules, multiple
- ☐ Lung nodules, multiple < 6mm, stable on prior exam
- ☐ Non-small cell lung cancer (NSCLC), monitor
- ☐ Non-small cell lung cancer (NSCLC), non-metastatic, assess treatment response
- ☐ Non-small cell lung cancer (NSCLC), recurrence
- ☐ Non-small cell lung cancer (NSCLC), metastatic, assess treatment response

Is the patient an asymptomatic adult between 50 and 77 years old (or up to 80 yo if Medicaid patient)? Yes No

Is the patient completely free of any signs or symptoms of lung cancer? Yes No

Is this the first (baseline) CT or an annual exam?  Annual Baseline

Is the patient a current smoker or did they quit < 15 years ago? Current smoker Quit < 15 years ago

Was there a shared-decision making conversation that involved the use of one or more decision aids? Yes No

Did the conversation/aid(s) describe the benefits and harms of screening? Yes No


Did the conversation/aid(s) describe possible follow up diagnostic testing? Yes No

Did the conversation/aid(s) describe the risk of "over diagnosis"? Yes No

Did the conversation/aid(s) describe the risk of false positives? Yes No


Next Required Accept Cancel





# Nudge and Choice Architecture






A nudge...is any aspect of the choice architecture that **alters people's behavior in a predictable way without forbidding any options or significantly changing their economic incentives.**


To count as a mere nudge, the intervention **must be easy and cheap to avoid.** Nudges are NOT mandates. Putting fruit at eye level counts as a nudge. Banning junk food does not.







Effective consent rates, online experiment, as a function of default.



Effective consent rates, by country. Explicit consent (opt-in, gold) and presumed consent (opt-out, blue).

# Choice Architecture (Nudge): Categories

**Decision structure:** alter the utility of choice options through their arrangement in the decision

**Decision information:** increase the availability, comprehensibility, and/or personal relevance of information

**Decision assistance:** facilitate self-regulation





# Choice Architecture (Nudge): Categories

## Decision structure

- Setting a default option.
- Changing the ease of choosing certain options: either making a good option easier to choose, or a bad option harder to choose.
- Changing the saliency of certain options: either making a good option more noticeable, or a bad option less noticeable.



# Choice Architecture (Nudge): Categories

Provide social reference point. Initial piece of information that people rely on strongly when making subsequent judgments and decisions.

## Decision information

For example, a charity soliciting donations can tell donors that “most people donate \$20”, in order to nudge people to donate more money than they would otherwise.

Make information visible

Provide access to relevant information.



# Choice Architecture (Nudge): Categories

## Decision assistance


Reminding people to do something.

Change option consequences: adjusting incentives or consequences of a specific behavior.

Facilitate commitment: Encourage self or public commitment to counteract failures of self-control.



## Peripherally Inserted Central Catheter (PICC)



© 2015 Terese Winslow LLC  
U.S. Govt. has certain rights



## Annals of Internal Medicine

# The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method

Vineet Chopra, MD, MSc; Scott A. Flanders, MD; Sanjay Saint, MD, MPH; Scott C. Woller, MD; Naomi P. O'Grady, MD; Nasia Safdar, MD, PhD; Scott O. Trerotola, MD; Rajiv Saran, MD, PhD; Nancy Moureau, BSN, RN; Stephen Wiseman, PharmD; Mauro Pittiruti, MD; Elie A. Akl, MD, MPH, PhD; Agnes Y. Lee, MD, MSc; Anthony Courey, MD; Lakshmi Swaminathan, MD; Jack LeDonne, MD; Carol Becker, MHSA; Sarah L. Krein, PhD, RN; and Steven J. Bernstein, MD, MPH

## Project Goals

1. increase proportion of midline catheters
2. decrease lumens of PICCs







## Order Sets

### ❗ UCH Adult Midline - PICC Placement and Care ⤴

**Always use a midline if appropriate.**

**If PICC line needed, minimize number of lumens.**

**Multiple lumen catheters = greater risk of infection and thrombosis.**

**INR must be  $< 3.0$  and platelets  $> 50,000$ .**


**If CKD/dialysis patient, order Hohn catheter instead.**

Please call the PICC team with specific requests.

#### ▼ General

##### ▼ ❗ Main Indication for IV Access

- ☐ Discharging with a Line
- ☐ Short-Term IV Access (Less Than 15 Days)
- ☐ Long-Term IV Access (Greater Than 15 Days)
- ☐ Frequent Phlebotomy
- ☐ Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)



Decision Information

Intervention order-set





## Decision Structure

▼ General

▼ Main Indication for IV Access

☐ Discharging with a Line

☒ Short-Term IV Access (Less Than 15 Days)

☒ Is patient discharging with a line or needing access for vasopressors, chemotherapy, or TPN?

☒ Yes

Your patient likely requires a PICC line based on your response to the previous question.

☒ IR PICC line

☒ Sign

☐ No

☐ Long-Term IV Access (Greater Than 15 Days)

☐ Frequent Phlebotomy

☐ Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)

▼ Central/Midline Line Approved for Use and for Blood Draws

☒ Central line approved for use

Routine, UNTIL DISCONTINUED starting Today at 1912 Until Specified  
PICC RN to Release, Sign & Hold

▼ IV access Placement and Care

☒ NS Flush (Heparin Contraindicated)



## Decision Information

▼ General

▼ Main Indication for IV Access

☐ Discharging with a Line

☐ Short-Term IV Access (Less Than 15 Days)

☐ Long-Term IV Access (Greater Than 15 Days)

☒ ☒ Frequent Phlebotomy

☐ IR Midline (Consider for LESS THAN 6 days)

☐ IR PICC line (Preferred for 6 days or More)

☐ Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)

▼ Central/Midline Line Approved for Use and for Blood Draws

☒ Central line approved for use

Routine, UNTIL DISCONTINUED starting Today at 1912 Until Specified  
PICC RN to Release, Sign & Hold

▼ IV access Placement and Care

☒ NS Flush (Heparin Contraindicated)

NS injection flush 10 mL  
10 mL, Intra-catheter, EVERY MORNING, First Dose Tomorrow at 0600, PICC RN to Re

And

NS injection flush 10 mL

Intervention order-set (cont.)







IR PICC line Decision Information ✓ Accept ✗ Cancel

Priority:

! New line or Replacement

! Desired number of lumens

! If patient to be discharged with PICC line, Physician/Ordering Clinic/Dept is aware of their responsibility to order patient's supplies, make arrangements for home health care and education prior to placement of PICC Line:



! Responsible provider pager number and after hours or weekend pager (if applicable):

Intervention PICC order



Increased midline usage as a proportion of all lines.

Increased proportion of single lumen PICCs as a proportion of all PICCs.





## Red Blood Cell (pRBC) Transfusion Recommendations

pRBCs are most likely APPROPRIATE in the following clinical scenarios:

- Hgb < 7 g/dL OR Hgb < 8 with CV disease AND symptoms
- Hemodynamically unstable patient with an acute bleed
- Perioperative acute blood loss anemia with expected Hgb < 7
- Cytotoxic chemotherapy with expected Hgb < 7
- Anemia with symptoms that are intolerable without transfusion

**Transfuse 1 unit at a time unless Hgb <6.0 or bleeding out**



**COST = ~\$700  
Per Unit**

50% of non-OR, non-MTP, inpatient transfusions **DID NOT** meet guidelines



# Prepare Order

## Original

☒ Prepare RBCs for Transfusion (must have Type and Screen available) ✓ Accept ✗ Cancel

Priority:  Routine STAT

Prepare: !  1 Units 2 Units 3 Units 4 Units 5 Units 6 Units  
10 Units 20 Units

Special requirements:

☐ Save as patient's requirements?

Transfusion Indications ☐ Perioperative ☐ Anemia ☐ Other (Specify)

Is this patient suspected or known to have a hematologic malignancy or congenital immunodeficiency?  
Yes No

Donor source Directed donor Autologous

Date of surgery, if applicable

Liver transplant only - indicate risk level  
Low (Order 5 units) Medium (Order 10 units)   
High (Order 20 units) Other (Specify)

Comments: + Add Comments (F6)

Add-on: No specimen type selected

✓ Accept ✗ Cancel



Decision Structure

## Intervention

Prepare RBCs for Transfusion (must have Type and Screen available), 1 Units ✓ Accept ✗ Cancel Remove

Priority:  Routine STAT

Prepare:  Units 1 Units

Special requirements:

☐ Save as patient's requirements?


Is this patient suspected or known to have a hematologic malignancy or congenital immunodeficiency?  
Yes No

Date of surgery, if applicable

Liver transplant only - indicate risk level  
Low (Order 5 units) Medium (Order 12 units)   
High (Order 20 units)

Comments: + Add Comments (F6)

Last Resulted: Lab Test Results





# Transfuse Order

Original

☒ Transfuse RBC

Priority:

Transfuse:  Units

Has signed consent been obtained?

Transfusion duration per unit in hours

Comments:

Last Resulted:
 

Component	Time Elapsed	Value	Range	Status
Hemoglobin	127 days (12/17/19 0000)	11.1	g/dL	Final result
	127 days (12/17/19 0000)	12.0	g/dL	Final result



Decision Structure



Decision Structure + Information

Intervention

Transfuse RBC: 1 Units

Priority:

Process Inst.:
 Transfuse:  Units

Transfusion Indications

Transfusion duration per unit in hours

Transfuse RBC: 1 Units

Accept

Cancel

Remove

P

Priority:

Routine

Process
Inst.:

Transfuse:

1

Units

1 Units

! Transfusion Indications

If Hgb 6.9 g/dL or less – indications not displayed

Transfusion duration per unit in hours

1

2

3

4

Rapid infuser

Maximum rate


Other (please specify)



Decision Structure

Does *overt* clinical-decision support (CDS) change provider behavior?

If so, how should it be displayed?





▼ Red Blood Cells

**! Potential Patient Harm - Consider Restrictive Transfusion Strategy**

Lab Results Last 3 days.

Component	Value	Date/Time
Hemoglobin	7.5 (A)	05/12/2021 2246

The Hemoglobin (Hgb) is greater than 6.9 g/dL which is tolerated by most hospitalized, stable patients. Transfusion above this level may result in harm to your patient.

**Limit transfusions to patients:**

1. Hgb <7 g/dL
2. Hgb <8 g/dL AND with known cardiovascular disease WITH symptom of ischemia
3. Hemodynamically unstable with an acute bleed
4. Preoperative acute blood loss anemia with expected Hgb nadir < 7 g/dL
5. Cytotoxic chemotherapy with expected nadir Hgb < 7g/dL
6. Anemia with symptoms that are intolerable without transfusion

Transfusing 1 Unit at a time is preferred

BestPractice Advisory - Bruce, Stella

**Attention (1)**

**! Potential Patient Harm (#8010)**

Consider Restrictive Transfusion Strategy

Hemoglobin	Date	Value	Ref Range	Status
	04/18/2021	7.5 (A)	12.1 - 16.3 g/dL	Corrected

Your patients Hemoglobin (Hgb) is greater than 6.9 g/dL which is well tolerated by most hospitalized, stable patients. Transfusing above this level may result in harm to your patient.

Transfusing 1 unit at a time is preferred

**Remove** the following orders?


☒ **Transfuse RBC: 1 Units**  
Routine, Transfuse 1 Units

Acknowledge Reason

Non-Interruptive Conditional Alert

Interruptive Conditional Alert  
“BPA”

# Results



Order (Set) Modify	Order (Set) Modify + In-line CDS	Order (Set) Modify + Interruptive CDS
--------------------	----------------------------------	---------------------------------------

pre-intervention = 2/1/2019-4/5/2021  
post-intervention = 4/6/2021-4/5/2022  
NOTE: early COVID pandemic period (3/3/2020 - 8/24/2020) were removed

Characteristic <sup>1</sup>	Overall, N = 10,451 <sup>1</sup>	Group 1, N = 3,254 <sup>1</sup>	Group 2, N = 3,675 <sup>1</sup>	Group 3, N = 3,522 <sup>1</sup>
compliant_type <sup>2</sup>				
compliant <sup>2</sup>	5,239 (50.2%) <sup>2</sup>	1,599 (49.2%) <sup>2</sup>	1,743 (47.5%) <sup>2</sup>	1,897 (53.9%) <sup>2</sup>
non-compliant_hgb <sup>2</sup>	4,682 (44.8%) <sup>2</sup>	1,503 (46.2%) <sup>2</sup>	1,740 (47.4%) <sup>2</sup>	1,439 (40.9%) <sup>2</sup>
non-compliant_units <sup>2</sup>	520 (5.0%) <sup>2</sup>	150 (4.6%) <sup>2</sup>	189 (5.1%) <sup>2</sup>	181 (5.1%) <sup>2</sup>
missing <sup>2</sup>	10 <sup>2</sup>	2 <sup>2</sup>	3 <sup>2</sup>	5 <sup>2</sup>
<sup>1</sup> n (%) <sup>2</sup>				

NO difference between groups



Characteristic?	Overall, N = 32,032 <sup>1</sup> ?	pre, N = 21,580 <sup>1</sup> ?	post, N = 10,452 <sup>1</sup> ?
compliant?	15,055 (47.0%)?	9,816 (45.5%)?	5,239 (50.2%)?
missing?	33?	23?	10?
<sup>1</sup> n (%)?			


Model results indicate a significant difference (p < 0.001) in compliance between the pre period and the post period, after accounting for linear time and provider.



Estimated number of units “saved” in one-year

1827





Decision Assistance

**Facilitate commitment:** Encourage self and/or public commitment



15%

\$2.45

20%

\$3.26

25%

\$4.08

Custom Tip Amount

No Tip



Decision Information

**Provide social reference point.**



Decision Structure







## Chronic Opioid Patients

Data as of: 10/31/2014

Go Back

	Total of Current Opioid Patients	Panel Size (12-mon)	% of Panel on Chronic Opioids	Total of 1-Utox Patients (6-mon)	% Utox Completed	Total of Contract Patients (ever)	% of Opioid Contract (ever)	Total of Contract Patients (12-mon)	% of Opioid Contract (12-mon)	Patients Not Seen (Med) within 3-mon	% Not Seen within 3-mon	Patients Seen By BH within 3-mon	% Seen By BH within 3-mon	Facility
Provider 1	7	870	0.80%	7	100.00%	6	85.71%	3	42.86%	0	0.00%	3	42.86%	CHC Site 1
Provider 2	55	1239	4.44%	35	63.64%	49	89.09%	41	74.55%	5	9.09%	2	3.64%	CHC Site 2
Provider 3	53	1182	4.48%	42	79.25%	47	88.68%	36	67.92%	4	7.55%	4	7.55%	CHC Site 3
Provider 4	4	172	2.33%	3	75.00%	4	100.00%	2	50.00%	0	0.00%	0	0.00%	CHC Site 4
Provider 5	65	828	7.85%	33	50.77%	18	27.69%	7	10.77%	5	7.69%	12	18.46%	CHC Site 5
Provider 6	21	811	2.59%	19	90.48%	20	95.24%	16	76.19%	2	9.52%	5	23.81%	CHC Site 6
Provider 7	4	1129	0.35%	4	100.00%	3	75.00%	3	75.00%	0	0.00%	1	25.00%	CHC Site 7
Provider 8	27	1207	2.24%	11	40.74%	18	66.67%	7	25.93%	1	3.70%	5	18.52%	CHC Site 4
Provider 9	76	1046	7.27%	48	63.16%	32	42.11%	8	10.53%	2	2.63%	9	11.84%	CHC Site 8
Provider 10	2	836	0.24%	2	100.00%	2	100.00%	1	50.00%	0	0.00%	1	50.00%	CHC Site 3
Provider 11	1	29	3.45%	1	100.00%	0	0.00%	0	0.00%	0	0.00%	1	100.00%	CHC Site 2
Provider 12	9	1102	0.82%	6	66.67%	6	66.67%	4	44.44%	0	0.00%	2	22.22%	CHC Site 3
Provider 13	18	410	4.39%	15	83.33%	12	66.67%	9	50.00%	0	0.00%	7	38.89%	CHC Site 5
Provider 14	3	191	1.57%	3	100.00%	3	100.00%	1	33.33%	0	0.00%	2	66.67%	CHC Site 5

## Chronic Opioid Patients

Provider 1

	Gender	Race	Last Med Encounter w/ PCP	Next Medical Visit	Last Utox Date	Currently On Opioid (Y/N)	Under Opioid Contract (Y/N)	Last BH Date	Next BH Visit	Last Visited BH Provider	Last Visited BH Site
Patient 1	F	Hispanic	10/xx/2014	10/xx/2014	7/xx/2014	Y	Y	1/xx/2014		BH Provider 1	CHC Site 1
Patient 2	F	White	8/xx/2014		8/xx/2014	Y	N	10/xx/2014		BH Provider 1	CHC Site 1
Patient 3	M	Black or African American	9/xx/2014	10/xx/2014	7/xx/2014	Y	Y				
Patient 4	M	Hispanic	10/xx/2014		10/xx/2014	Y	Y	2/xx/2013		BH Provider 2	CHC Site 2
Patient 5	M	Hispanic	10/xx/2014	10/xx/2014	6/xx/2014	Y	Y	10/xx/2014	11/xx/2014	BH Provider 1	CHC Site 1
Patient 6	F	White	8/xx/2014	10/xx/2014	8/xx/2014	Y	Y	8/xx/2014		BH Provider 1	CHC Site 1
Patient 7	F	Hispanic	10/xx/2014		6/xx/2014	Y	Y	8/xx/2013		BH Provider 3	CHC Site 1



Information

al reference point.

ture







Decision Structure

**Changing the salience of certain options.**







# The FIVE “**Rights**” of Clinical Decision Support

## The Right **Information**

...to the Right (**Person**)...

...in the Right **Format**...

...through the Right **Channel**...

...at the Right **Point in the Workflow**.



## Important (1)



⚠️ **TOBACCO USE ASSESSMENT:** Order a Nicotine Dependence Consult for any patient who uses tobacco or e-cigarettes.

**ASK: Have you used any form of tobacco, including electronic cigarettes, in the last 30 days?**

**If NO:** Indicate their tobacco use status below, and click **ACCEPT**

**IF YES:** Please give them the following message, and click **ACCEPT**

**"We have all patients who use tobacco visit with a specialist to learn more about how tobacco affects your health. This is an important part of your care at Mayo Clinic. If you need more information, your provider can help you."**

Order

Do Not Order

🏠 **NICOTINE DEPENDENCE CONSULT**

Add Visit Diagnosis

Do Not Add

**Nicotine Dependence**

Acknowledge Reason

Never used tobacco

Used tobacco more than 30 days ago


In tobacco treatment

© Epic Systems Corporation. Used with permission

✓ **Accept**

**Dismiss**






# Design Thinking

Producing the best design *with* your users.







Design thinking brings together what is **desirable** from a human point of view with what is technologically **feasible** and economically **viable**.








1


DESIGN THE RIGHT THING

2


DESIGN THINGS RIGHT



A



# The Design Thinking process...





## EMPATHIZE



“Standing in long lines at the pharmacy, keeping up with expiration dates, making sure you take this medicine with food and that one on an empty stomach—it can be overwhelming.”











## DEFINE

The World Health Organization estimates that roughly 50 percent of patients in the US with chronic illnesses don't take that medication exactly as prescribed—mistakes that can be deadly.

- Patients often are confused about medication dosing and timing.
- Patients are frustrated with their current prescription management.








Ideation is a process of “going wide” in terms of concepts and outcomes to explore a wide solution space – both a **large quantity and broad diversity of ideas.**





Prototyping is getting projects out of your head and into the world – allowing your users to interact and give feedback.

Done with low budget, interactive, tangible items.




PROTOTYPE



**TEST**

Testing allows gathering feedback and refining the solutions.







## Breakout #1



15 minutes

1. Introduce yourself and the problem you are trying to solve.


2. **Brainstorm at least THREE possible interventions.**

- Based on your problem understanding.
- One must "defy gravity"
- One must be a nudge.





**A**





# What if I could draw blood without poking the patient?





## Breakout #1



15 minutes


1. Introduce yourself and the problem you are trying to solve.

2. **Brainstorm at least THREE possible interventions.**


- Based on your problem understanding.
- One must "defy gravity"
- One must be a nudge.




# Why design thinking...?



prioritizes  
empathy



involves  
highly diverse and  
collaborative teams



encourages action-  
oriented rapid  
prototyping



user-derived insights  
rather than top-down  
hypotheses






Bring it back down to earth...






# Prioritizing Your Interventions





***Epic***



Education



# Tracking Your Interventions





HELLO? CAN ANYBODY HEAR ME?



How will you **KNOW** your intervention is happening?



## OUTCOME

Inpatient DVT rate per 1000 patients

## PROCESS STRUCTURE

- % of patients receiving appropriate prophylaxis
- SCDs and pumps in room
  - and applied to patient?

**Intervention** = EHR guidance based on risk

- Risk score completion in EHR

## BALANCE

Bleeding rates.





# Pediatric Vaccination Schedules

## OUTCOME

Percentage of patients (in a clinic) vaccinated  
(NOTE: actual outcome is disease)

## PROCESS

% of patients offered vaccine  
% of patients declined

## STRUCTURE

**Intervention** = pop-up reminder

- % of alerts ignored / followed

## BALANCE


Provider alert fatigue

Lower well-child exams for lower SES with a mistrust of vaccines.



How do you **KNOW** your intervention is working?





How do you KNOW your intervention is safe?





A top-down photograph of two white coffee cups on a dark grey table. The cup on the left is filled with a latte and has a spoon resting on its saucer. A hand is visible at the top left, holding the handle of this cup. The cup on the right is mostly empty, with some coffee residue at the bottom, and also has a spoon on its saucer. A hand is visible at the bottom right, holding the handle of this cup. A wooden tray is partially visible under the right cup. A black and white checkered cloth is in the top left corner. A semi-transparent white rectangular box is centered over the image, containing the text 'BREAK-TIME' and 'Come back at \*\*\*pm MT!'.

**BREAK-TIME**

Come back at \*\*\*pm MT!



# User-centered Design







BestPractice Advisory - Testa, Pt

### Attention (1)

⚠ Potential Patient Harm (#8010)

**Consider Restrictive Transfusion Strategy**

Your patients Hemoglobin (Hgb) is greater than 6.9 g/dL which is well tolerated by most hospitalized, stable patients. Transfusing above this level may result in harm to your patient.

**Limit transfusions to patients:**

1. Hgb <7 g/dL
2. Hgb <8 g/dL AND with known cardiovascular disease WITH symptoms of ischemia
3. Hemodynamically unstable with an acute bleed
4. Perioperative acute blood loss anemia with expected Hgb nadir <7 g/dL
5. Cytotoxic chemotherapy with expected nadir Hgb < 7g/dL
6. Anemia with symptoms that are intolerable without transfusion

**Transfusing 1 unit at a time is preferred**

Hemoglobin Date	Value	Ref Range	Status
02/04/2021	7.5 (A)	12.1 - 16.3 g/dL	Final

**Remove the following orders?**

Remove
Keep
Transfuse RBC: 1 Units  
Routine, Transfuse 1 Units

**Acknowledge Reason**

Pt has an indication listed
Other (See Comments)

Enter Comment

Accept

Tested with Users

©Epic Systems, 2021

BestPractice Advisory - Bruce, Stella

### Attention (1)

⚠ Potential Patient Harm (#8010)

**Consider Restrictive Transfusion Strategy**

Hemoglobin Date	Value	Ref Range	Status
04/15/2022	7.5 (A)	12.1 - 16.3 g/dL	Final

Your patients Hemoglobin (Hgb) is greater than 6.9 g/dL which is well tolerated by most hospitalized, stable patients. Transfusing above this level may result in harm to your patient.

**Transfusing 1 unit at a time is preferred**

**Remove the following orders?**

Remove
Keep
Transfuse RBC: 1 Units  
Routine, Transfuse 1 Units

**Acknowledge Reason**

Hgb <8 g/dL AND with known cardiovascular...
Hemodynamically unstable with an acute b...
Perioperative acute blood loss anemia wi...
Cytotoxic chemotherapy with expected nad...
Anemia with symptoms that are intolerabl...
Other (Specify)

Enter Comment

Accept

Final Version

- ✓ Order Red Blood Cells
  - ✓ Prepare RBCs for Transfusion (must have Type and Screen available), 1 Units
    - Routine
    - ! Prepare 1 Units
- ☐ Transfuse RBC

### Tested with Users

- ✓ Order Red Blood Cells
  - ✓ Prepare RBCs for Transfusion (must have Type and Screen available), 1 Units
    - Routine
    - ! Prepare 1 Units
  - ✓ Transfuse RBC: 1 Units
    - ! Routine, Transfuse 1 Units

### Final Version

“If I actually wanted to transfuse them and I was moving fast, I would not see (the transfuse order)...I would ignore it and it wouldn't be until half an hour down the road that somebody would tell me, hey, you don't have the order in for transfuse RBCs.”





# Definition


Coined in Donald A. Norman's research laboratory in UCSD

User is FRONT & CENTER

Involve users throughout the design process

An iterative design process

Overlays design thinking




# Design Thinking & UCD

Design thinking: way of thinking for developing new products, services, solutions for social problems

User-centered design: method for improving usability, user experience of a certain product or service

User-centered design example:  
Transgender Health Information Resource



Design thinking example:  
New York City Subway Map











## Clients



## Users






# User Testing Methods




“Question Asking Method”



“Task Performance Measurement”



Physiological monitoring technology (ie: BP, HR, head/ eye tracking)



Usability testing in both simulated/ real-time environments



Questionnaires, surveys, observations, focus-group interviews, self-reporting logs, workshops




Interactive process over time





# Pre-Mortem Analysis



# Pre-Mortem Analysis

- Comes at the beginning of a project rather than the end
- Unlike a typical problem identification session in which stakeholders are asked what *might* go wrong.

**Assumes that the project has been implemented and failed,  
then asks “What did go wrong?”**



# Pre-Mortem Analysis

- quickly engages QI key partners
- creates an environment of psychological safety
- way to gather feedback to maximize the effectiveness of implementing planned QI projects
- vs. user-testing -- allows for a more global assessment of potential failures rather than beyond the individual user-level.










Defines surgical category by color

Shelf labels indicate specific procedure in coordinating colors

Shelf liners help prevent tears in outer pouch, ensuring sterility and reducing waste





## Breakout #2



**10 minutes**


# Conduct a Pre-Mortem

Assume this project has been implemented and failed

**“What went wrong?” “Why?”**









## Breakout #2



**15 minutes**



# Conduct a Pre-Mortem

Assume this project has been implemented and failed

**“What went wrong?” “Why?” “Now what?”**



# Pre-Mortem Analysis: Brain Writing



**6** participants  
**3** ideas / participant  
**5** times passing ideas









**You don't know the  
best solutions...but  
your users do!**



**You must talk to  
them to find out.**



**There are methods  
for how to get the  
best out of your  
users.**



**It is critical to  
ensure your  
interventions are  
*safe before*  
implemented.**



